Authorized purpose: Second Opinion Panoramic is an automated image-processing aid that identifies and marks regions of interest for caries, periapical radiolucency, and impacted third molars on panoramic radiographs of permanent teeth in patients aged 16 years and older.
Clinical role
Concurrent second-reader support for labeled panoramic dental findings.
Images and patients
X-ray/Radiography · Permanent teeth; caries, periapical radiolucency, and impacted third molars
Key limitation
Keep in mind: The FDA labeling states that the software should not replace a full patient evaluation or be solely relied on for diagnosis. Age, dentition, radiograph, and professional-review limits apply.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Second Opinion Panoramic is an automated image-processing aid that identifies and marks regions of interest for caries, periapical radiolucency, and impacted third molars on panoramic radiographs of permanent teeth in patients aged 16 years and older.
Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Permanent teeth; caries, periapical radiolucency, and impacted third molars Input: Panoramic radiographs of permanent teeth in patients aged 16 years and older.
Who uses it?Intended users: Dental health professionals.
What does the software produce?Output: Marked regions of interest for caries, periapical radiolucency, and impacted third molars.
What is its most important limitation?Key limitation: The FDA labeling states that the software should not replace a full patient evaluation or be solely relied on for diagnosis. Age, dentition, radiograph, and professional-review limits apply.
Clinical takeaway. Clinical role: Second Opinion Panoramic is an automated image-processing aid that identifies and marks regions of interest for caries, periapical radiolucency, and impacted third molars on panoramic radiographs of permanent teeth in patients aged 16 years and older.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports a standalone study and a fully-crossed MRMC study; ground truth for an enriched set of 795 images was consensus of at least three out of four board-certified dentists. The standalone study met its primary endpoint, with wAFROC figure of merit values of 0.9788, 0.8113, and 0.7211 for impacted third molars, periapical radiolucency, and caries. In the MRMC study, periapical radiolucency detection showed a lesion level wAFROC difference of 0.0705 (95% CI: 0.04–0.10). Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Second Opinion Panoramic is an automated image-processing aid that identifies and marks regions of interest for caries, periapical radiolucency, and impacted third molars on panoramic radiographs of permanent teeth in patients aged 16 years and older.
The FDA labeling states that the software should not replace a full patient evaluation or be solely relied on for diagnosis. Age, dentition, radiograph, and professional-review limits apply.
The exact FDA document reports a standalone study and a fully-crossed MRMC study; ground truth for an enriched set of 795 images was consensus of at least three out of four board-certified dentists. The standalone study met its primary endpoint, with wAFROC figure of merit values of 0.9788, 0.8113, and 0.7211 for impacted third molars, periapical radiolucency, and caries. In the MRMC study, periapical radiolucency detection showed a lesion level wAFROC difference of 0.0705 (95% CI: 0.04–0.10). Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Second Opinion® PR was clinically tested as a standalone device in comparison to the predicate device, Second Opinion, using both a standalone clinical study and a fully-crossed MRMC study." … "The ground truth (GT) was established using the consensus approach based on agreement among at least three out of four expert readers.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports a standalone study and a fully-crossed MRMC study; ground truth for an enriched set of 795 images was consensus of at least three out of four board-certified dentists. The standalone study met its primary endpoint, with wAFROC figure of merit values of 0.9788, 0.8113, and 0.7211 for impacted third molars, periapical radiolucency, and caries. In the MRMC study, periapical radiolucency detection showed a lesion level wAFROC difference of 0.0705 (95% CI: 0.04–0.10). Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Second Opinion® PR was clinically tested as a standalone device in comparison to the predicate device, Second Opinion, using both a standalone clinical study and a fully-crossed MRMC study." … "The ground truth (GT) was established using the consensus approach based on agreement among at least three out of four expert readers.". Read from the exact FDA decision document on 2026-11-14.
Do not generalize an endpoint across populations, thresholds, versions, or workflows; use only exact evidence.metrics records.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
Do not generalize an endpoint across populations, thresholds, versions, or workflows; use only exact evidence.metrics records.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K250525 FDA evidence package for Second Opinion® Panoramic
DesignFDA 510(k) decision evidence and product verification for the exact submission.
PopulationPermanent teeth; caries, periapical radiolucency, and impacted third molars
Scopeexact submission
Tested versionSecond Opinion Panoramic
IndependenceSponsor or vendor study
K250525
FDA-submitted evidence for the exact decision; it is not independent clinical validation and does not establish local production qualification.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
No record matched K250525 by exact native submission identifier in the 2026-09-02 openFDA snapshot; this does not exclude product-family, later-version, or adverse-event information.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Panoramic radiographs of permanent teeth in patients aged 16 years and older.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes automated processing of panoramic radiographs and marked output for dental-professional review; the complete local interface contract remains unknown.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes Second Opinion Panoramic as using cloud-based environments to conduct processing, with images sent via an API to machine learning modules and the detection output rendered in a user interface. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "The primary and secondary predicate devices and subject device are similar devices in the following ways:" … "Technology characteristics: All devices employ computer vision and machine learning to output detections, use cloud-based environments to conduct processing". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: Marked regions of interest for caries, periapical radiolucency, and impacted third molars.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes Second Opinion Panoramic as using cloud-based environments to conduct processing, with images sent via an API to machine learning modules and the detection output rendered in a user interface. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The primary and secondary predicate devices and subject device are similar devices in the following ways:" … "Technology characteristics: All devices employ computer vision and machine learning to output detections, use cloud-based environments to conduct processing". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact FDA package describes automated processing of panoramic radiographs and marked output for dental-professional review; the complete local interface contract remains unknown.
Pearl's data protection page describes GDPR-aligned EU/UK data storage in AWS Dublin, EU-US/Swiss-US/UK Data Privacy Framework certifications maintained by the U.S. Department of Commerce, and data and systems security standards including AES-256 cryptography with certificate rotation, HIPAA-compliant access logging across Pearl systems, SonarQube static code analysis and vulnerability scanning, and TLS 1.2 encryption in transit with AES-256 at rest.
Vendor-wide
Checked 2026-10-27
Vendor statement; the referenced certifications were not independently verified. Page scope is Pearl's software platform including Second Opinion products; exact-release scope is not established.
The exact FDA package describes automated processing of panoramic radiographs and marked output for dental-professional review; the complete local interface contract remains unknown.
Monitor labeling, software version, complaints, recalls, failed inputs, overrides, and postmarket signals against the exact submission and installed configuration.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
27Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The snapshot contained no PubMed or ClinicalTrials.gov candidates; no evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price or commercial contract for the exact submission and version was identified.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission
No exact-product payer coverage or reimbursement determination was identified in reviewed public material.
Authorized purpose: Assist trained professionals in assessing radiographic knee osteoarthritis and its sclerosis, joint-space-narrowing, and osteophyte features on standing fixed-flexion knee radiographs.
Authorized purpose: Overjet Iris is a web-based dental PACS for storing, viewing, and supporting image-quality review of two-dimensional intraoral radiographs, panoramic images, and color photographs.
Authorized purpose: Analyzes bitewing, periapical, and panoramic intraoral radiographs from patients aged 3 years and older to identify and localize specified suspected dental findings, historical treatments, and normal anatomy; diagnostic use remains with trained dental professionals.
Authorized purpose: YSIO X.pree is a digital X-ray system for whole-body radiographic imaging, including skull, chest, abdomen, and extremities, to support diagnostic and therapeutic decisions.
Modality
X-ray/Radiography
Anatomy
Whole body, including skull; chest; abdomen; and extremities
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.